This article is more than 5 years old. Information may no longer be current.

Aldeyra submits IND application for phase 2 testing of uveitis treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aldeyra Therapeutics has submitted an investigational new drug application to the U.S. Food and Drug Administration to conduct phase 2 clinical testing of its product, NS2, for the treatment of noninfectious anterior uveitis.

“The submission of an IND for NS2 in the treatment of noninfectious anterior uveitis is a major milestone for Aldeyra and is another step forward in the execution of our development strategy,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in a company press release. “NS2 has the potential to reduce or eliminate the use of steroids in the treatment of this disease, which we believe would significantly enhance the treatment options for these patients and improve their long-term ocular health.”

NS2 was developed to reduce inflammation, fibrosis and tissue damage caused by inflammatory ocular diseases by trapping free aldehydes.

The company intends to begin the phase 2 trial in early 2015, pending FDA approval of the application, according to the release.